{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:59:35Z","timestamp":1787507975501,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clim.2025.110457","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:16:38Z","timestamp":1740140198000},"page":"110457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients"],"prefix":"10.1016","volume":"274","author":[{"given":"Chaoyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haocheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianni","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clim.2025.110457_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"5","key":"10.1016\/j.clim.2025.110457_bb0010","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1021\/acschemneuro.9b00041","article-title":"Autoimmune attack of the neuromuscular junction in myasthenia gravis: nicotinic acetylcholine receptors and other targets","volume":"10","author":"Paz","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.clim.2025.110457_bb0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","article-title":"Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology","volume":"146","author":"Pham","year":"2023","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.clim.2025.110457_bb0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","article-title":"Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders","volume":"21","author":"Huijbers","year":"2022","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.clim.2025.110457_bb0025","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.clim.2025.110457_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.clim.2025.110457_bb0035","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (adapt): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.clim.2025.110457_bb0040","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1007\/s00415-024-12454-6","article-title":"Rituximab alone is as effective as associated with steroids on naive patients with generalized myasthenia gravis","volume":"271","author":"H\u00e9raud","year":"2024","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.clim.2025.110457_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40263-023-01059-8","article-title":"Myasthenia gravis treatment: from old drugs to innovative therapies with a glimpse into the future","volume":"38","author":"Crisafulli","year":"2024","journal-title":"CNS Drugs"},{"issue":"23","key":"10.1016\/j.clim.2025.110457_bb0050","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of ivig and plex in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.clim.2025.110457_bb0055","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.22139","article-title":"Comparative analysis of therapeutic options used for myasthenia gravis","volume":"68","author":"Mandawat","year":"2010","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.clim.2025.110457_bb0060","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaneurol.2014.17","article-title":"Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis","volume":"71","author":"Liew","year":"2014","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.clim.2025.110457_bb0065","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.clim.2025.110457_bb0070","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther. Apher. Dial."},{"issue":"7","key":"10.1016\/j.clim.2025.110457_bb0075","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1468-1331.2010.03017.x","article-title":"Course and prognosis of myasthenia gravis: a systematic review","volume":"17","author":"Mao","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.clim.2025.110457_bb0080","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00134-013-2960-6","volume":"39","author":"Damian","year":"2013","journal-title":"Intensive Care Med."},{"issue":"10","key":"10.1016\/j.clim.2025.110457_bb0085","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210005","article-title":"Epidemiologic study of myasthenia gravis in the elderly us population: a longitudinal analysis of the medicare claims database, 2006-2019","volume":"103","author":"Bruckman","year":"2024","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.clim.2025.110457_bb0090","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2025.110457_bb0095","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.clim.2025.110457_bb0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of america","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.clim.2025.110457_bb0105","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2025.110457_bb0110","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"18","key":"10.1016\/j.clim.2025.110457_bb0115","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The mg composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.clim.2025.110457_bb0120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does igg modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.clim.2025.110457_bb0125","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"Fcrn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2025.110457_bb0130","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal fc receptor in human immunity: function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2025.110457_bb0135","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology--mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.clim.2025.110457_bb0140","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood.V74.1.326.326","article-title":"High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance","volume":"74","author":"Basta","year":"1989","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clim.2025.110457_bb0145","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1055\/s-0037-1613331","article-title":"Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the fcrn receptor","volume":"88","author":"Hansen","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.clim.2025.110457_bb0150","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete fcrn dependence for intravenous ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.clim.2025.110457_bb0155","doi-asserted-by":"crossref","first-page":"844","DOI":"10.2215\/CJN.01701105","article-title":"Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience","volume":"1","author":"Vo","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.clim.2025.110457_bb0160","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel fcrn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"17","key":"10.1016\/j.clim.2025.110457_bb0165","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an fcrn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.clim.2025.110457_bb0170","article-title":"Prospective cohort study evaluating efficacy and safety of efgartigimod in chinese generalized myasthenia gravis patients","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clim.2025.110457_bb0175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuroscience.2020.03.009","article-title":"Antibodies and receptors: from neuromuscular junction to central nervous system","volume":"439","author":"Vincent","year":"2020","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.clim.2025.110457_bb0180","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1172\/JCI1248","article-title":"Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss","volume":"102","author":"Guyon","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.clim.2025.110457_bb0185","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/mus.22177","article-title":"Endplate contributions to the safety factor for neuromuscular transmission","volume":"44","author":"Ruff","year":"2011","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.clim.2025.110457_bb0190","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting fcrn for immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2025.110457_bb0195","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1526-4610.1998.3804317.x","article-title":"Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications","volume":"38","author":"Finkel","year":"1998","journal-title":"Headache"},{"key":"10.1016\/j.clim.2025.110457_bb0200","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421997381","article-title":"The importance of fcrn in neuro-immunotherapies: from igg catabolism, fcgrt gene polymorphisms, ivig dosing and efficiency to specific fcrn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clim.2025.110457_bb0205","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420986747","article-title":"Vntr2\/vntr3 genotype in the fcgrt gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis","volume":"14","author":"Su","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625000324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625000324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:21:04Z","timestamp":1742343664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661625000324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":41,"alternative-id":["S1521661625000324"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2025.110457","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2025.110457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110457"}}